866-997-4948(US-Canada Toll Free)

Growth Hormone Deficiency - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Sep 2013

Category :

Metabolic Disorders

No. of Pages : 96 Pages


Global Markets Directs, \'Growth Hormone Deficiency Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Growth Hormone Deficiency, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Growth Hormone Deficiency. Growth Hormone Deficiency Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Growth Hormone Deficiency.
  • A review of the Growth Hormone Deficiency products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Growth Hormone Deficiency pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Growth Hormone Deficiency.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Growth Hormone Deficiency pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Growth Hormone Deficiency Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Growth Hormone Deficiency 10
Growth Hormone Deficiency Therapeutics under Development by Companies 12
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Growth Hormone Deficiency Therapeutics - Products under Development by Companies 19
Companies Involved in Growth Hormone Deficiency Therapeutics Development 20
Samyang Corporation 20
Teva Pharmaceutical Industries Limited 21
Access Pharmaceuticals, Inc. 22
Flamel Technologies S.A. 23
Emisphere Technologies, Inc. 24
Theratechnologies Inc. 25
Hanall Pharmaceutical Co., Ltd. 26
LG Life Sciences, Ltd 27
Critical Pharmaceuticals Limited 28
Aileron Therapeutics, Inc. 29
Ambrx, Inc. 30
Braasch Biotech LLC 31
Phage Biotechnology Corporation 32
Versartis, Inc. 33
Bolder Biotechnology, Inc. 34
PharmaEssentia Corporation 35
Ascendis Pharma A/S 36
Pfenex Inc. 37
Growth Hormone Deficiency - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
somatropin biobetter - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
somatropin SR - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
somatropin SR - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
tesamorelin acetate - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
somatropin - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Pegylated Growth Hormone - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Peg-Human Growth Hormone - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
ARX-201 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
VRS-317 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
somatropin - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
ACP-001 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
HL-032 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
somatropin - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
CP-016 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
CobOral hGH - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
BBT-031 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
somatropin biosimilar - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Pegylated Recombinant Human Growth Hormone - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ALRN-5281 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
somatropin biosimilar - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Human Growth Hormone Sustained Release - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
CJ-40002 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
TV-1106 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
somatropin - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
SYN-20100504RU - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Growth Hormone Deficiency Therapeutics - Drug Profile Updates 75
Growth Hormone Deficiency Therapeutics - Discontinued Products 85
Growth Hormone Deficiency Therapeutics - Dormant Products 86
Growth Hormone Deficiency - Product Development Milestones 87
Featured News & Press Releases 87
Jun 16, 2013: Versartis Presents Positive Results From First Pediatric Clinical Study Of VRS-317 At ENDO 2013 Annual Meeting 87
Jun 13, 2013: Prolor Biotech To Present New Data On Its Long-acting Human Growth Hormone At ENDO 2013 88
Jun 04, 2013: Prolor Biotech Initiates Pivotal Phase III Trial Of Its Longer-acting Version Of Human Growth Hormone 88
May 31, 2013: Biopartners Announces Positive CHMP Opinion For Once-Weekly Somatropin Biopartners 89
May 30, 2013: BioPartners Receives CHMP Positive Opinion For Somatropin 90
May 07, 2013: Aileron Therapeutics Successfully Completes Stapled Peptide Clinical Trial 91
Apr 30, 2013: Versartis Announces Publication Of Positive Phase I Data Of VRS-317 In Journal of Clinical Endocrinology & Metabolism 92
Apr 25, 2013: Ipsen Expects Increlex Supply Interruption Due To Supplier Manufacturing Issues 92
Feb 26, 2013: Aileron Therapeutics To Highlight Stapled Peptide Pipeline At 2013 AsiaTIDES Meeting 93
Feb 13, 2013: Prolor Biotech\'s Longer-acting Human Growth Hormone Receives Orphan Drug Designation In Europe 93

Appendix 95
Methodology 95
Coverage 95
Secondary Research 95
Primary Research 95
Expert Panel Validation 95
Contact Us 96
Disclaimer 96

List of Table


Number of Products Under Development for Growth Hormone Deficiency, H2 2013 10
Products under Development for Growth Hormone Deficiency - Comparative Analysis, H2 2013 11
Number of Products under Development by Companies, H2 2013 13
Number of Products under Development by Companies, H2 2013 (Contd..1) 14
Comparative Analysis by Late Stage Development, H2 2013 15
Comparative Analysis by Mid Clinical Stage Development, H2 2013 16
Comparative Analysis by Early Clinical Stage Development, H2 2013 17
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 18
Products under Development by Companies, H2 2013 19
Samyang Corporation, H2 2013 20
Teva Pharmaceutical Industries Limited, H2 2013 21
Access Pharmaceuticals, Inc., H2 2013 22
Flamel Technologies S.A., H2 2013 23
Emisphere Technologies, Inc., H2 2013 24
Theratechnologies Inc., H2 2013 25
Hanall Pharmaceutical Co., Ltd., H2 2013 26
LG Life Sciences, Ltd, H2 2013 27
Critical Pharmaceuticals Limited, H2 2013 28
Aileron Therapeutics, Inc., H2 2013 29
Ambrx, Inc., H2 2013 30
Braasch Biotech LLC, H2 2013 31
Phage Biotechnology Corporation, H2 2013 32
Versartis, Inc., H2 2013 33
Bolder Biotechnology, Inc., H2 2013 34
PharmaEssentia Corporation, H2 2013 35
Ascendis Pharma A/S, H2 2013 36
Pfenex Inc., H2 2013 37
Assessment by Monotherapy Products, H2 2013 38
Assessment by Stage and Route of Administration, H2 2013 40
Assessment by Stage and Molecule Type, H2 2013 42
Growth Hormone Deficiency Therapeutics - Drug Profile Updates 75
Growth Hormone Deficiency Therapeutics - Discontinued Products 85
Growth Hormone Deficiency Therapeutics - Dormant Products 86

List of Chart


Number of Products under Development for Growth Hormone Deficiency, H2 2013 10
Products under Development for Growth Hormone Deficiency - Comparative Analysis, H2 2013 11
Products under Development by Companies, H2 2013 12
Late Stage Products, H2 2013 15
Mid Clinical Stage Products, H2 2013 16
Early Clinical Stage Products, H2 2013 17
Discovery and Pre-Clinical Stage Products, H2 2013 18
Assessment by Monotherapy Products, H2 2013 38
Assessment by Route of Administration, H2 2013 39
Assessment by Stage and Route of Administration, H2 2013 40
Assessment by Molecule Type, H2 2013 41
Assessment by Stage and Molecule Type, H2 2013 42

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *